Fig. 6

RASAL2 c.2423 A > G variant confers resistance to anti-EGFR antibody in CRC cells. (a) and (b) The proliferation ability of RASAL2 wild-type and mutant HT29 cells treated with cetuximab over a 3-day period. HT29 cells were transfected with wild-type (c.2423 A > A) and mutant RASAL2 (c.2423 A > G), and cell proliferation was assessed using the MTT viability assay after treatment with cetuximab at concentrations of 0.5 and 1.5 µg/mL (left). Cell viability was expressed as a percentage of the absorbance reading on day 0, and the results on day 3 were compared between HT29 cells with and without cetuximab treatment (right). (c) and d, The proliferation ability of RASAL2 wild-type and mutant LIM1215 cells treated with cetuximab at concentrations of 0.5 and 1.5 µg/mL over a 3-day period. Results are presented as mean ± SEM from three independent experiments. Statistical analysis was conducted using Student’s t-test. **p < 0.01, ***p < 0.001; N.S., p ≥ 0.05 (not significant).